Allarity Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ALLR moving today?
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ALLR.
ALLR insider activity
Allarity Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$23K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-10-02 | 2025-09-30 | Graff Jeremy R. | Insider | sell | $1.58 | 14,613 | 24,881 | $23K | SEC Form 4 |
ALLR contract awards, year to date.
Public federal awards linked to this ticker.
ALLR lobbying filings, year to date.
Registered lobbying filings matched to Allarity Therapeutics, Inc. Common Stock.